Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024.
Marine MaurelJennifer HowardEsther KisslingFrancisco PozoGloria Pérez-GimenoSilke BudaNoémie SèveAdele McKennaAdam MeijerAna Paula RodriguesIván Martínez-BazIvan MlinarićNeus Latorre-MargalefGergő TúriMihaela LazărClara MazagatosAitziber EcheverriaStephen AbelaMarc BourgeoisAusenda MachadoRalf DürrwaldGoranka PetrovićBeatrix OrosziLigita JancorieneAlexandru MarinPetr HusaRoisin DuffyFrederika DijkstraVirtudes Gallardo GarcíaLuise GoerlitzVincent EnoufCharlene BennettMariëtte HooiveldRaquel GuiomarCamino Trobajo-SanmartínVesna Višekruna VučinaTove Samuelsson HageyAna Sofía Lameiras AzevedoJesús CastillaGerd XuerebBénédicte DelaereVerónica GómezKristin TolksdorfSabrina BacciNathalie NicolayMarlena KaczmarekAngela Mc Rosenull nullPublished in: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2024)
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.